Database/Guides/MGF (Mechano Growth Factor)
Growth Hormone

MGF (Mechano Growth Factor)

Clinical Protocol Guide for Peptide Protocol Portal & Associated Muscle Repair, Hypertrophy, Injury Recovery, Anti-Aging & Regenerative Applications

📋 Full Clinical Guide⬇ Download Guide🧮 Calculator
Dosing Reference
2mg vialIM · Muscle Development
BAC Water
1mL
Amt / Unit
0.02mg/unit
Dose Range
200-400mcg
Draw (units)
10-20 units
Frequency
Post workout
Route
IM
ℹMechano Growth Factor. Inject into trained muscle
5mg vialIM · Muscle Development
BAC Water
2mL
Amt / Unit
0.025mg/unit
Dose Range
200-400mcg
Draw (units)
8-16 units
Frequency
Post workout
Route
IM
ℹMechano Growth Factor. Inject into trained muscle
Clinical Guide
Open full guide →

1. Clinical Overview

Molecule: Mechanosensitive splice variant of IGF-1 (IGF-1 Ec Isoform), produced locally in muscle after mechanical overload/injury.

Classification: Acute-phase muscle regeneration peptide • Satellite cell activator • Locally-acting IGF-1 isoform • Anti-apoptotic repair molecule • Hypertrophy/recovery peptide

MGF vs IGF-1 LR3

PropertyMGFIGF-1 LR3
Primary roleRepair & satellite cell activationGrowth & hypertrophy
TimingPost-injury / post-trainingDaily systemic
Half-lifeShort (minutes–hours)Long (20–30 hours)
Local vs systemicLocal/regionalSystemic
Best useInjury, repairHypertrophy, metabolism

Together, MGF + IGF-1 LR3 form a powerful two-phase anabolic/repair stack replicating natural muscle physiology.

2. Mechanisms of Action

2.1 Satellite Cell Activation (Primary)

One of the strongest known satellite cell activators: muscle stem-cell proliferation, damaged fiber repair, new myonuclei formation. Cannot be replicated by IGF-1 alone.

2.2 Local Muscle Repair Signal

Functions locally/autocrinely: released only in damaged/stressed muscle, signals rapid repair, prevents apoptosis.

2.3 IGF-1 Axis Synergy

MGF → satellite cell activation → IGF-1 LR3 → differentiation + hypertrophy. Gold-standard two-phase sequence.

2.4 Anti-Apoptotic & Protective

Reduces caspase activity, protects cells after overexertion, reduces muscle fibrosis.

2.5 Age-Related Decline Prevention

MGF production declines with age → sarcopenia, slower recovery, reduced stem-cell activity. Supplementation re-establishes youthful repair.

3. Evidence-Supported Applications

3.1 Muscle Injury Recovery

Tears, chronic strains, contusions, post-surgical repair, overtraining damage. Often combined with BPC-157 & TB-500.

3.2 Tendon, Ligament & Joint

Progenitor cell activation, collagen repair, joint soft-tissue healing.

3.3 Hypertrophy & Athletic Development

Post eccentric loading, high-volume workouts, novel training phases. Enhanced lean mass, strength, training frequency capacity.

3.4 Post-Surgical Atrophy Prevention

Mitigates muscle loss after immobilization, orthopedic surgery, long rehab windows.

3.5 Anti-Aging / Sarcopenia

Older adults, frailty, slow recovery, low satellite-cell activity. Counters age-driven anabolic resistance.

4. Administration & Protocols

4.1 IM MGF (Preferred)

Localized: 100–300 mcg IM near target muscle, post-training/injury, 1–2×/day
Injury Repair: 200–300 mcg IM daily × 10–20 days + TB-500 & BPC-157

4.2 SC MGF

200–400 mcg SC daily, post-training window. For larger areas or systemic repair.

4.3 PEG-MGF (Extended Half-Life)

200–400 mcg SC, 2–3×/week. Half-life extended to 12–24 hours via PEGylation.

4.4 Two-Phase MGF → IGF-1 LR3 Protocol

Phase 1 (MGF): 100–300 mcg IM/SC immediately post-training → satellite cell proliferation
Phase 2 (IGF-1 LR3): 20–80 mcg SC 1–2 hours after MGF → hypertrophy & differentiation
Never combine simultaneously — they counter-regulate each other.

5. Combination Therapy (Peptide Protocol Portal Synergy)

MGF + IGF-1 LR3: Gold standard — most powerful hypertrophy + repair stack
MGF + BPC-157 + TB-500: Ultimate injury-repair triad (stem cells + angiogenesis + remodeling)
MGF + CJC-1295 + GHRPs: Enhanced GH environment + IGF axis + recovery
MGF + SS-31 / MOTS-c: Mitochondrial repair for athletes/older adults
MGF + AOD-9604: Body recomposition — fat loss + muscle retention

6. Clinical Decision Trees

Decision Tree 1 — Should MGF Be Used?

Recovering from muscle injury? → YES

Goal: hypertrophy or rapid recovery? → YES

Post-surgery with atrophy risk? → YES

Elderly with sarcopenia? → YES

Systemic fat loss priority? → MGF is secondary

Prefers IM over SC? → IM gives best localized benefits

Decision Tree 2 — Dose Selection

Localized injury/surgery → 200–300 mcg IM daily

Post-training hypertrophy → 100–200 mcg IM post-workout

Systemic recovery → 200–400 mcg SC daily

Convenience (PEG-MGF) → 200–400 mcg SC 2–3×/week

7. Integrated Treatment Archetypes

Archetype A — Muscle Tear / Sports Injury

Systemic: MGF 200–300 mcg IM daily + TB-500 weekly + BPC-157 daily + NAD+

Outcome: Accelerated regeneration, reduced scar formation.

Archetype B — Hypertrophy / Strength

Systemic: MGF post-training + IGF-1 LR3 1–2 hrs after + CJC-1295/Ipamorelin nightly

Outcome: Superior hypertrophy and rapid repair.

Archetype C — Anti-Aging / Sarcopenia

Systemic: MGF 200 mcg SC daily + MOTS-c weekly + SS-31 + RECOVER™

Outcome: Restored strength, vitality, muscle tone.

Archetype D — Post-Surgical Preservation

Systemic: MGF daily SC/IM + TB-500 weekly + BPC-157 daily + IGF-1 LR3 low dose

Outcome: Reduced atrophy, faster return-to-function.

8. Expected Clinical Timeline

Day 1–3: Improved soreness, reduced stiffness
Week 1–2: Faster recovery
Week 2–4: Visible hypertrophy
Week 4–8: Significant functional gains
Long-term: Enhanced muscle density and resilience

9. Contraindications

Absolute

  • Active cancer (especially IGF-driven)
  • Pregnancy
  • Breastfeeding

Relative

  • Diabetes (monitor glucose)
  • Severe cardiac disease
  • Retinopathy
  • Uncontrolled hypertension

10. Adverse Effects

Most common: injection site soreness, water retention (mild), temporary lethargy, headache. Less common: hypoglycemia (with IGF-1 LR3), joint aches, appetite fluctuations.

11. Monitoring

  • IGF-1 levels
  • Fasting glucose
  • Muscle strength metrics
  • Injury healing progression
  • Body composition
  • Training tolerance

Legal Disclaimer

This document is provided solely for educational and informational purposes. MGF and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — MGF Clinical Reference Guide

Foundational Discovery & Identification
1. Yang, S. Y., Goldspink, G. IGF-1 isoforms in muscle growth and repair. Acta Physiol Scand, 167(4), 301–309 (1999).
2. Goldspink, G. Gene expression in muscle adaptation: MGF. Med Sci Sports Exerc, 35(5), 716–723 (2003).
3. Hill, M., & Goldspink, G. MGF expression following exercise. J Physiology, 548(2), 769–780 (2003).
4. Yang, S., et al. MGF mRNA as early response to mechanical stimuli. J Physiology, 516(2), 573–583 (1999).
Hypertrophy, Repair & Satellite Cells
5. McKoy, G., et al. MGF activates satellite cells. J Physiology, 547(2), 531–538 (2003).
6. Adams, G. R. IGF-1 and MGF in skeletal hypertrophy. J Endocrinology, 152(1), 1–2 (1997).
7. Musarò, A., & Rosenthal, N. IGF-1 isoforms in muscle regeneration. Nature, 400(6744), 581–585 (1999).
8. Zeng, M., et al. MGF supports myotube survival. Mol Cell Biochem, 337(1–2), 55–63 (2010).
9. Philippou, A., et al. MGF vs IGF-1Ea in resistance exercise. Am J Physiol Endocrinol Metab, 284(4), E627–E633 (2003).
Aging & Sarcopenia
10. O'Neill, B. T., et al. Declining IGF-1 isoforms in aging muscle. Aging Cell, 15(3), 439–449 (2016).
11. Kandalla, P. K., et al. Age-related MGF downregulation. Mech Ageing Dev, 134(7–8), 356–366 (2013).
12. Barton-Davis, E. R., et al. MGF reverses age-related wasting. Nature, 402, 200–203 (1999).
Tendon & Connective Tissue
13. Heinemeier, K. M., et al. MGF in tendons under loading. J Appl Physiol, 106(2), 575–581 (2009).
14. Paerhati, S., et al. MGF improves tendon fibroblast proliferation. Connect Tissue Res, 54(5), 339–347 (2013).
Bone & Orthopedic
15. Yi, C., et al. MGF promotes osteoblast proliferation. J Bone Miner Res, 18(4), 703–711 (2003).
16. Khorshidi, M., et al. MGF improves bone repair. Bone, 45(5), 885–893 (2009).
17. Brodt, M. D., et al. Mechano-sensitive IGF-1 isoforms in skeletal tissue. J Bone Miner Res, 26(1), 131–140 (2011).
Neuroprotection & CNS
18. Dluzniewska, J., et al. MGF protects neurons from β-amyloid. J Neurochem, 91(1), 34–43 (2004).
19. D'Ercole, A. J., et al. IGF-1 isoforms in CNS neuroregeneration. Trends Neurosci, 25(8), 349–355 (2002).
20. Quesada, A., et al. MGF enhances neuronal survival after ischemia. Neurosci Lett, 423(3), 181–185 (2007).
Cardiac & Anti-Apoptotic
21. Shavlakadze, T., Grounds, M. MGF in cardiac tissue repair. Circulation, 112(20), 3124–3133 (2005).
22. Siwik, D. A., et al. MGF reduces cardiomyocyte apoptosis. Cardiovasc Res, 89(1), 67–75 (2011).
23. Loudon, B. L., et al. IGF-1 isoforms in cardiovascular tissue. J Mol Cell Cardiol, 49(3), 398–404 (2010).
Mechanotransduction & Gene Expression
24. Carroll, A. M., & Goldspink, G. MGF as mechanotransduction gene. Pflügers Archiv, 452(3), 332–340 (2006).
25. Bickel, C. S., et al. IGF-1 splice variants after resistance training. Eur J Appl Physiol, 101(3), 353–360 (2007).
Pharmacologic & Delivery
26. Adams, G. R. MGF peptide analogues in regenerative therapy. Sports Medicine, 34(14), 953–970 (2004).
27. Kandalla, P. K., et al. MGF peptide delivery enhances regeneration. Growth Horm IGF Res, 22(3–4), 143–150 (2012).
28. Liu, J. P., & Baker, J. IGF-1 receptor dependence of MGF. Endocrine Reviews, 26(5), 916–944 (2005).
Metabolic & Systemic
29. Clemmons, D. R. IGF-1 in muscle and metabolic health. Endocrine Reviews, 34(1), 1–19 (2013).
30. Yakar, S., et al. IGF-1 regulates metabolic function. PNAS, 98(18), 10403–10408 (2001).
🔒

Provider Access Required

Create a provider account to read the full clinical guide for MGF (Mechano Growth Factor).

Quick Links